Tracing TMEM106B fibril deposition in aging and Parkinson’s disease with dementia brains

Abstract

Transmembrane protein 106B (TMEM106B), previously identified as a risk factor in frontotemporal lobar degeneration, has recently been detected to form fibrillar aggregates in the brains of patients with various neurodegenerative diseases (NDs) and normal elders. While the specifics of when and where TMEM106B fibrils accumulate in human brains, as well as their connection to aging and disease progression, remain poorly understood. Here, we identified an anti-body (NBP1-91311) that directly binds to TMEM106B fibrils extracted from the brain in vitro and to Thioflavin S-positive TMEM106B fibrillar aggregates in brain sections. We discovered that TMEM106B fibrils deposit in the human brain in an age-dependent manner. Notably, the TMEM106B fibril load in the brains of Parkinson’s disease with dementia patients was significantly higher than in age-matched elders. Additionally, we found that TMEM106B fibrils predominantly accumulate in astrocytes and neurons and do not co-localize with the pathological deposition formed by other amyloid proteins such as α-synuclein, Aβ, and Tau. Our work provides a comprehensive analysis of the burden and cellular distribution of TMEM106B fibrils in human brains, underscoring the impact of both aging and disease conditions on TMEM106B fibril deposition. This highlights the potential significance of TMEM106B fibrils in various age-related NDs.

Keywords

TMEM106B fibril / aging / neurodegenerative disease / amyloid aggregation / Parkinson’s disease with dementia

References

[1] Lang CM, Fellerer K, Schwenk BM, et al. Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration. J Biol Chem 2012;287:19355–65.

[2] Brady OA, Zheng Y, Murphy K, et al. The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function. Hum Mol Genet 2013;22:685–95.

[3] Schwenk BM, Lang CM, Hogl S, et al. The FTLD risk factor TMEM106B and MAP6 control dendritic trafficking of lysosomes. EMBO J 2014;33:450–67.

[4] Van Deerlin VM, Sleiman PM, Martinez-Lage M, et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet 2010;42:234–9.

[5] Finch N, Carrasquillo MM, Baker M, et al. TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology 2011;76:467–74.

[6] Tropea TF, Mak J, Guo MH, et al. TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia. Ann Neurol 2019;85:801–11.

[7] Gallagher MD, Suh E, Grossman M, et al. TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathol 2014;127:407–18.

[8] Cruchaga C, Graff C, Chiang HH, et al. Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. Arch Neurol 2011;68:581–6.

[9] Llibre-Guerra JJ, Lee SE, Suemoto CK, et al. A novel temporal- predominant neuro-astroglial tauopathy associated with TMEM106B gene polymorphism in FTLD/ALS-TDP. Brain Pathol 2021;31:267–82.

[10] Hu Y, Sun JY, Zhang Y, et al. rs1990622 variant associates with Alzheimer’s disease and regulates TMEM106B expression in human brain tissues. BMC Med 2021;19:11.

[11] Jun G, Ibrahim-Verbaas CA, Vronskaya M, et al; IGAP Consortium. A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry 2016;21:108–17.

[12] Rutherford NJ, Carrasquillo MM, Li M, et al. TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease. Neurology 2012;79:717–8.

[13] Hong S, Dobricic V, Ohlei O, et al; Alzheimer’s Disease Neuroimaging Initiative (ADNI). TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer’s disease biomarker levels. Alzheimer’s Dement 2021;17:1628–40.

[14] Mao F, Robinson JL, Unger T, et al. TMEM106B modifies TDP-43 pathology in human ALS brain and cell-based models of TDP-43 proteinopathy. Acta Neuropathol 2021;142:629–42.

[15] Vass R, Ashbridge E, Geser F, et al. Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta Neuropathol 2011;121:373–80.

[16] Manini A, Ratti A, Brusati A, et al. TMEM106B acts as a modifier of cognitive and motor functions in amyotrophic lateral sclerosis. Int J Mol Sci 2022;23:9276.

[17] Adams HH, Verhaaren BF, Vrooman HA, et al. TMEM106B influences volume of left-sided temporal lobe and interhemispheric structures in the general population. Biol Psychiatry 2014;76:503–8.

[18] Li Z, Farias FHG, Dube U, et al. The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion. Acta Neuropathol 2020;139:45–61.

[19] Rhinn H, Abeliovich A. Differential aging analysis in human cerebral cortex identifies variants in TMEM106B and GRN that regulate aging phenotypes. Cell systems 2017;4:404–415.e5.

[20] Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239–59.

[21] Yang Y, Arseni D, Zhang W, et al. Cryo-EM structures of amyloid-β 42 filaments from human brains. Science 2022;375:167–72.

[22] Fitzpatrick AWP, Falcon B, He S, et al. Cryo-EM structures of tau filaments from Alzheimer’s disease. Nature 2017;547:185–90.

[23] Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003;24:197–211.

[24] Crowther RA, Daniel SE, Goedert M. Characterisation of isolated alpha-synuclein filaments from substantia nigra of Parkinson’s disease brain. Neurosci Lett 2000;292:128–30.

[25] Yang Y, Shi Y, Schweighauser M, et al. Structures of α- synuclein filaments from human brains with Lewy pathology. Nature 2022;610:791–5.

[26] Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130–3.

[27] Arseni D, Hasegawa M, Murzin AG, et al. Structure of pathological TDP-43 filaments from ALS with FTLD. Nature 2022;601:139–43.

[28] Arseni D, Chen R, Murzin AG, et al. TDP-43 forms amyloid filaments with a distinct fold in type A FTLD-TDP. Nature 2023;620:898–903.

[29] Li D, Liu C. Conformational strains of pathogenic amyloid proteins in neurodegenerative diseases. Nat Rev Neurosci 2022;23:523–34.

[30] Lee EB, Porta S, Michael Baer G, et al. Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol 2017;134:65–78.

[31] Holec SAM, Woerman AL. Evidence of distinct α-synuclein strains underlying disease heterogeneity. Acta Neuropathol 2021;142:73–86.

[32] Xu Q, Ma Y, Sun Y, et al. Protein amyloid aggregate: Structure and function. Aggregate 2023;4:e333–e333.

[33] Robinson JL, Lee EB, Xie SX, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain 2018;141:2181–93.

[34] Fan Y, Zhao Q, Xia W, et al. Generic amyloid fibrillation of TMEM106B in patient with Parkinson’s disease dementia and normal elders. Cell Res 2022;32:585–8.

[35] Schweighauser M, Arseni D, Bacioglu M, et al. Age-dependent formation of TMEM106B amyloid filaments in human brains. Nature 2022;605:310–4.

[36] Jiang YX, Cao Q, Sawaya MR, et al. Amyloid fibrils in FTLD-TDP are composed of TMEM106B and not TDP-43. Nature 2022;605:304–9.

[37] Chang A, Xiang X, Wang J, et al. Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases. Cell 2022;185:1346–1355.e15.

[38] Double KL, Dedov VN, Fedorow H, et al. The comparative biology of neuromelanin and lipofuscin in the human brain. Cell Mol Life Sci 2008;65:1669–82.

[39] Selkoe DJ. The molecular pathology of Alzheimer’s disease. Neuron 1991;6:487–98.

[40] Forloni G, Lucca E, Angeretti N, et al. Amidation of beta-amyloid peptide strongly reduced the amyloidogenic activity without alteration of the neurotoxicity. J Neurochem 1997;69:2048–54.

[41] Feng T, Lacrampe A, Hu F. Physiological and pathological functions of TMEM106B: a gene associated with brain aging and multiple brain disorders. Acta Neuropathol 2021;141:327–39.

[42] Nelson PT, Wang WX, Partch AB, et al. Reassessment of risk genotypes (GRN, TMEM106B, and ABCC9 variants) associated with hippocampal sclerosis of aging pathology. J Neuropathol Exp Neurol 2015;74:75–84.

[43] Yu L, De Jager PL, Yang J, et al. The TMEM106B locus and TDP-43 pathology in older persons without FTLD. Neurology 2015;84:927–34.

[44] Hokkanen SRK, Kero M, Kaivola K, et al; EClipSE Collaboration. Putative risk alleles for LATE-NC with hippocampal sclerosis in populationrepresentative autopsy cohorts. Brain pathol 2020;30:364–72.

[45] Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain 2019;142:1503–27.

[46] Zhou X, Brooks M, Jiang P, et al. Loss of Tmem106b exacerbates FTLD pathologies and causes motor deficits in progranulin-deficient mice. EMBO Rep 2020;21:e50197.

[47] Werner G, Damme M, Schludi M, et al. Loss of TMEM106B potentiates lysosomal and FTLD-like pathology in progranulin-deficient mice. EMBO Rep 2020;21:e50241.

[48] Feng T, Mai S, Roscoe JM, et al. Loss of TMEM106B and PGRN leads to severe lysosomal abnormalities and neurodegeneration in mice. EMBO Rep 2020;21:e50219.

[49] Klein ZA, Takahashi H, Ma M, et al. Loss of TMEM106B ameliorates lysosomal and frontotemporal dementia-related phenotypes in progranulin-deficient mice. Neuron 2017;95:281–296.e6.

[50] Perneel J, Neumann M, Heeman B, et al. Accumulation of TMEM106B C-terminal fragments in neurodegenerative disease and aging. Acta Neuropathol 2023;145:285–302.

[51] Vicente CT, Perneel J, Wynants S, et al. C-terminal TMEM106B fragments in human brain correlate with disease-associated TMEM106B haplotypes. Brain. 2023;146:4055–64.

[52] Neumann M, Perneel J, Cheung S, et al. Limbic-predominant age-related TDP-43 proteinopathy (LATE-NC) is associated with abundant TMEM106B pathology. Acta Neuropathol 2023;146:163–6.

[53] Shen Y, Yu WB, Shen B, et al. Propagated α-synucleinopathy recapitulates REM sleep behaviour disorder followed by parkinsonian phenotypes in mice. Brain 2020;143:3374–92.

[54] Schnell SA, Staines WA, Wessendorf MW. Reduction of lipofuscinlike autofluorescence in fluorescently labeled tissue. J Histochem Cytochem 1999;47:719–30.

[55] Scheres SHW. Amyloid structure determination in RELION-3.1. Acta crystallogr D Struct Biol 2020;76:94–101.

[56] Emsley P, Lohkamp B, Scott WG, et al. Features and development of Coot. Acta Crystallogr Sect D Biol Crystallogr 2010;66:486–501.

[57] Adams PD, Afonine PV, Bunkóczi G, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr Sect D Biol Crystallogr 2010;66:213–21.

RIGHTS & PERMISSIONS

The Author(s) 2024. Published by Oxford University Press on behalf of Higher Education Press.